Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Enanta Pharmaceuticals (ENTA) Operating Expenses (2016 - 2025)

Enanta Pharmaceuticals' Operating Expenses history spans 14 years, with the latest figure at $29.9 million for Q4 2025.

  • For Q4 2025, Operating Expenses fell 26.26% year-over-year to $29.9 million; the TTM value through Dec 2025 reached $140.0 million, down 20.85%, while the annual FY2025 figure was $150.7 million, 20.42% down from the prior year.
  • Operating Expenses reached $29.9 million in Q4 2025 per ENTA's latest filing, down from $33.5 million in the prior quarter.
  • In the past five years, Operating Expenses ranged from a high of $58.1 million in Q4 2021 to a low of $29.9 million in Q4 2025.
  • Average Operating Expenses over 5 years is $47.9 million, with a median of $49.9 million recorded in 2021.
  • Peak YoY movement for Operating Expenses: skyrocketed 33.65% in 2021, then dropped 26.26% in 2025.
  • A 5-year view of Operating Expenses shows it stood at $58.1 million in 2021, then fell by 7.68% to $53.6 million in 2022, then decreased by 1.32% to $52.9 million in 2023, then fell by 23.42% to $40.5 million in 2024, then fell by 26.26% to $29.9 million in 2025.
  • Per Business Quant, the three most recent readings for ENTA's Operating Expenses are $29.9 million (Q4 2025), $33.5 million (Q3 2025), and $37.2 million (Q2 2025).